Inhibition of Histone Deacetylases 1, 2, and 3 Enhances Clearance of Cholesterol Accumulation in Niemann-Pick C1 Fibroblasts
Open Access
- 27 May 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 4 (3) , 1136-1148
Abstract
Niemann-Pick disease type C1 (NPC1) is a rare genetic cholesterol storage disorder caused by mutations in the NPC1 gene. Mutations in this transmembrane late endosome protein lead to loss of normal cholesterol efflux from late endosomes and lysosomes. It has been shown that broad spectrum histone deacetylase inhibitors (HDACi's) such as Vorinostat correct the cholesterol accumulation phenotype in the majority of NPC1 mutants tested in cultured cells. In order to determine the optimal specificity for HDACi correction of the mutant NPC1s, we screened 76 HDACi's of varying specificity. We tested the ability of these HDACi's to correct the excess accumulation of cholesterol in patient fibroblast cells that homozygously express NPC1I1061T, the most common mutation. We determined that inhibition of HDACs 1, 2, and 3 is important for correcting the defect, and combined inhibition of all three is needed to achieve the greatest effect, suggesting a need for multiple effects of the HDACi treatments. Identifying the specific HDACs involved in the process of regulating cholesterol trafficking in NPC1 will help to focus the search for more specific druggable targets.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (R01 NS092653)
- Ara Parseghian Medical Research Foundation
- National Niemann-Pick Disease Foundation (11)
This publication has 92 references indexed in Scilit:
- Niemann–Pick type C 1 function requires lumenal domain residues that mediate cholesterol-dependent NPC2 bindingProceedings of the National Academy of Sciences, 2011
- Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblastsProceedings of the National Academy of Sciences, 2011
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapyClinical Epigenetics, 2010
- Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cellsProceedings of the National Academy of Sciences, 2010
- Chemical phylogenetics of histone deacetylasesNature Chemical Biology, 2010
- Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosisNature Chemical Biology, 2009
- Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cellsProceedings of the National Academy of Sciences, 2009
- Synthesis and Conformation−Activity Relationships of the Peptide Isosteres of FK228 and LargazoleJournal of the American Chemical Society, 2009
- NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomesProceedings of the National Academy of Sciences, 2008
- Total Synthesis and Biological Mode of Action of Largazole: A Potent Class I Histone Deacetylase InhibitorJournal of the American Chemical Society, 2008